November 29, 2023

OncoResponse Announces Initiation of Phase 1/2 Clinical Trial of OR502, anti-LILRB2 Antibody, in Subjects with Advanced Cancer

November 3, 2023

OncoResponse Announces Preclinical Data Highlighting OR502 anti-LILRB2 Antibody and OR641 Dual anti-LILRB2/1 Antibody at SITC 2023

October 26, 2023

OncoResponse Announces Two Poster Presentations at the Society for Immunotherapy of Cancer 38th Annual Meeting (SITC 2023)

September 6, 2023

OncoResponse Announces Appointment of Carol Gallagher to Board of Directors

May 18, 2023

OncoResponse Awarded $13 Million in Funding from CPRIT and Raises $14 Million in Added Funds from Investors to Advance Cancer Immunotherapy

April 19, 2023

OncoResponse Presents at AACR 2023 Annual Meeting Preclinical Data Highlighting Dual Antagonist Antibodies Targeting both LILRB1 and LILRB2

March 15, 2023

OncoResponse Announces Presentation of Preclinical Data on Dual Antibodies Targeting LILRB1 and LILRB2 at American Association for Cancer Research Annual Meeting (AACR) 2023

January 5, 2023

OncoResponse to Present at 41st Annual J.P. Morgan Healthcare Conference

November 11, 2022

OncoResponse Announces Preclinical Data Highlighting OR2805 Discovery from Elite Responder Platform and OR502 anti-LILRB2 Antibody at SITC 2022

October 5, 2022

OncoResponse Announces Poster Presentations at the Society for Immunotherapy of Cancer 37th Annual Meeting (SITC 2022)

September 7, 2022

OncoResponse Announces Clinical Supply Agreement with Regeneron to Evaluate OR2805 in Combination with Libtayo® (cemiplimab) in Patients with Advanced Cancer

August 2, 2022

OncoResponse Announces Drug Discovery Collaboration with University of Texas MD Anderson Cancer Center to Advance ‘Elite Responder’ Derived Cancer Immunotherapies

March 2, 2022

OncoResponse Announces Oral Presentation at Festival of Biologics World Immunotherapy Congress and World Antibody Congress 2022

November 22, 2021

OncoResponse to Present at Upcoming Investor Conferences

November 12, 2021

OncoResponse Presents Data on Multiple Immuno-oncology Agents at the Society for Immunotherapy of Cancer's 36th Annual Meeting (SITC 2021)

November 9, 2021

OncoResponse Appoints Renowned Immunologists Drs. Miriam Merad and David G. DeNardo to Scientific Advisory Board

November 2, 2021

OncoResponse Announces Initiation of Phase 1 Trial of OR2805 – Human Monoclonal Antibody Derived from Elite Responder to Cancer Immunotherapy – in Patients with Advanced Cancer

October 6, 2021

OncoResponse Announces Presentations at the Society for Immunotherapy of Cancer 36th Annual Meeting (SITC 2021)

July 7, 2021

OncoResponse Appoints Sean McCarthy to Board of Directors

May 11, 2021

OncoResponse Appoints Chris Russell as Chief Financial Officer

March 31, 2021

OncoResponse Raises $40.6 Million Series C Financing

April 14, 2020

OncoResponse Appoints Robert Lechleider, MD as Chief Medical Officer; Promotes Kamal Puri, PhD to Chief Scientific Officer

January 16, 2020

Just – Evotec Biologics announces product development and manufacturing agreement with OncoResponse

September 11, 2018

OncoResponse Raises $40 Million in Series B Financing

January 2, 2018

OncoResponse Expands Scientific Leadership with the Addition of Dr. Anil Singhal as Chief Scientific Officer and Dr. Kamal D. Puri as Vice President, Research and Development

April 4, 2017

OncoResponse to Present at BioCentury Future Leaders Conference

March 9, 2017

OncoResponse Announces Final Closing of $22.5M Series A Financing Round

October 10, 2016

OncoResponse Secures $7M in Supplemental Series A Funding

May 26, 2016

OncoResponse Secures Investment from Baxalta

January 7, 2016

OncoResponse and Oregon Health & Science University Collaborate to Identify Novel Immuno-Oncology Targets

October 6, 2015

MD Anderson, Theraclone Sciences form OncoResponse